Universitätsklinikum Ulm

Hospital


Location: Ulm, Germany (DE) DE

ISNI: -

ROR: https://ror.org/05emabm63

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab (CD-Bev) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in Patients with Recurrent Ovarian Cancer: a Prospective Randomized Phase iii Engot/GCiG-Intergroup Study (Ago Study Group, Ago-AUSTRiA, ANZGOG,GiNECO, SGCTG) (2020) Hanker L, Harter P, Sehoul L, Rau J, Canzler U, Schmalfeldt B, Thiel F, et al. Conference contribution Phase III PAOLA-1/ENGOT-OV25 Trial: Olaparib Plus Bevacizumab (BEV) As Maintenance Therapy in Patients (PTS) with Newly Diagnosed, Advanced Ovarian Cancer (OC) Treated with Platinum-Based Chemotherapy (PCH) Plus Bev (2020) De Gregorio N, Harter P, Sehouli L, Canzler U, Marme F, Buderath P, Lueck HJ, et al. Conference contribution Germline (G)BRCA1/2 Mutations (M) and Hematological Toxicities in Patients (PTS) with Triple Negative Breast Cancer (TNBC) Treated with Neoadjuvant Chemotherapy (NACT) (2020) Furlanetto J, Moebus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Luebbe K, et al. Conference contribution A Randomized, Double-Blind, Phase III Trial of Neoadjuvant Chemotherapy (NACT) with atezolizumab/Placebo in Patients with Triple-Negative Breast Cancer (TNBC) Followed by Adjuvant Continuation of atezolizumab/Placebo (Gepardouze) (2020) Loibl S, Jackisch C, Seiler S, Rastogi P, Huober L, Denkert C, Schneeweiss A, et al. Conference contribution Nilotinib (NIL) vs. NIL Plus Pegylated Interferon alpha2B (IFN) Induction and NIL or IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1+Chronic Myeloid Leukemia (CML) Patients (PTS) in Chronic Phase (2020) Ernst T, Saussele S, Burchert A, Baerlocher GM, Bruemmendorf TH, La Rosee PG, Heim D, et al. Conference contribution First Results of the Detect IVA Study -Everolimus Treatment in Patients with HER2-Negative, Hormone-Receptor Positive Metastatic Breast (MBC) Cancer and Circulating Tumor Cells (CTC) (2020) Friedl TWP, Krause S, Fasching P, Schneeweiss A, Mueller V, Riethdorf S, Taran FA, et al. Conference contribution Medizinische Betreuung von jungen Frauen mit Ullrich-Turner-Syndrom in Deutschland (2020) Dörr HG, Bettendorf M, Binder G, Braemswig J, Hauffa BP, Holterhus PM, Mohnike K, et al. Journal article Analysis of documented informed consent forms for computed tomography: Completeness and data quality in four clinics Analyse von dokumentierten Computertomographie-Aufklärungen: Vollständigkeit und Datenqualität in vier Kliniken (2020) Vogele D, Schöffski O, Efinger K, Schmidt SA, Beer M, Kildal D Journal article EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees (2020) Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, et al. Journal article Wedelolactone inhibits human cytomegalovirus replication by targeting distinct steps of the viral replication cycle (2020) Svrlanska A, Ruhland A, Marschall M, Reuter N, Stamminger T Journal article